The system aims to help paramedics on the ground to make the right clinical decisions instead of taking the patient to A&E.
News
Investigational atopic dermatitis drug hits late-stage endpoints
There is currently a “critical need” for additional treatment options for atopic dermatitis.
Review recommends screening upgrade to save more lives
Professor Sir Mike Richards makes several recommendations, with a key focus on improving uptake.
Pfizer launches ‘catfish’ counterfeit medicines campaign
The campaign is aimed at students who don’t know what they could be buying online.
FDA ‘yes’ for Eli Lilly’s Reyvow
The approval marks the first new class of acute migraine treatment approved by the FDA in more than two decades.
Survey reveals ‘workforce crisis’ in NHS
Performance statistics throughout the last year have shown “strain on an already stretched system.”
Tailor-made drug shows success in Batten disease
The process could pave the way for more rapid delivery of individualised treatments.
Rituxan hits targets in late-stage pemphigus vulgaris trial
The study is still ongoing, with patients participating in a 48-week safety follow-up period.
Novo, Bluebird Bio ink in vivo genome research agreement
The three-year collaboration will utilise Bluebird Bio’s proprietary mRNA-based megaTAL technology.
NHS to improve young people’s hospital mental health, learning disability and autism services
The services are all part of the NHS Long Term plan.
New mental health outreach funding for homeless
New teams will identify rough sleepers in need of help, support them to access a GP and then on to the new expert psychiatric help.
Clovis’ Rubraca approved for Cancer Drugs Fund
NICE initially rejected the drug for use on the NHS, citing uncertainties in evidence and questioning the pricing.
MGB Biopharma reveals positive mid-stage diarrhoea data
To date, MGB-BP-3 is the only antibiotic that has the killing power, combined with the speed of action, to eradicate the disease within the first few hours of exposure.
Sanofi opens new HQ
The “state of the art” facility will be the new base for 500 of the 1,200 employees in the UK.
GSK recalls prescription Zantac
The FDA claims to have found “unacceptable” levels of carcinogen in the medicine.
